Research
Hormonal
Cagrilintide, a novel amylin analogue, shows promising body weight reducing effects.
Cagrilintide may be an effective treatment for weight loss, especially when combined with other therapies.
StrongSupportsmedium confidence
Cagrilintide, a novel amylin analogue suitable for once-weekly administration, has shown promising body weight reducing effects alone and in combination with the glucagon-like peptide 1 receptor agonist semaglutide.
Why this rating
Based on the mention of clinical development and effects.
Source
Long-acting amylin analogues for the management of obesity
David S. Mathiesen et al. · Current Opinion in Endocrinology Diabetes and Obesity · 2022
reviewCited 37×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →